{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:35:52Z","timestamp":1793651752980,"version":"4.5.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872255"],"award-info":[{"award-number":["81872255"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20212012"],"award-info":[{"award-number":["BK20212012"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hepatocellular carcinoma (HCC) is a kind of tumor with high invasiveness, and patients with advanced HCC have a higher risk of early death. The aim of the present study was to identify the risk factors of early death in patients with advanced HCC and establish predictive nomograms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Death that occurred within 3\u00a0months of initial diagnosis is defined as early death. Patients diagnosed with stage IV HCC between 2010 and 2015 were collected from the Surveillance, Epidemiology, and End Results database for model establishment and verification. Univariable and multivariable logistic regression analyses were used to identify the risk factors. Predictive nomograms were constructed and an internal validation was performed. Decision curve analysis (DCA) was used to verify the true clinical application value of the models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 6603 patients (57% age\u2009&gt;\u200960, 81% male, 70% white, 46% married), 21% and 79% had stage IVA and IVB, respectively. On the multivariable analyses, risk factors for early deaths in patients with stage IVA were age, tumor size, histological grade, alpha-fetoprotein (AFP), fibrosis score, tumor stage (T stage), surgery, radiotherapy, and chemotherapy, and that in stage IVB were age, histological grade, AFP, T stage, node stage (N stage), bone metastasis, lung metastasis, surgery, radiotherapy, and chemotherapy. The areas under the curves (AUCs) were 0.830 (95% CI 0.809\u20130.851) and 0.789 (95% CI 0.768\u20130.810) in stage IVA and IVB, respectively. Nomograms comprising risk factors with the concordance indexes (<jats:italic>C<\/jats:italic>-indexes) were 0.820 (95% CI 0.799\u20130.841) in stage IVA and 0.785 (95% CI 0.764\u20130.0.806) in stage IVB for internal validation (Bootstrapping, 1000re-samplings). The calibration plots of the nomograms show that the predicted early death was consistent with the actual value. The results of the DCA analysis show that the nomograms had a good clinical application.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The nomograms can be beneficial for clinicians in identifying the risk factors for early death of patients with advanced HCC and predicting the probability of early death, so as to allow for individualized treatment plans to be accurately selected.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-022-02424-5","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T16:09:59Z","timestamp":1658246999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Risk factors and predictive nomograms for early death of patients with advanced hepatocellular carcinoma: a large retrospective study based on the SEER database"],"prefix":"10.1186","volume":"22","author":[{"given":"Haidong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanlong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Qing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yewei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"2424_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"2424_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","unstructured":"EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol"},{"key":"2424_CR3","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.3390\/cancers12102859","volume":"12","author":"C Kole","year":"2020","unstructured":"Kole C, Charalampakis N, Tsakatikas S, Vailas M, Moris D, Gkotsis E, Kykalos S, Karamouzis MV, Schizas D. Immunotherapy for hepatocellular carcinoma: a 2021 update. Cancers. 2020;12:2859.","journal-title":"Cancers"},{"key":"2424_CR4","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.21037\/apm-20-1876","volume":"10","author":"K Zhang","year":"2021","unstructured":"Zhang K, Tao C, Wu F, Wu J, Rong W. A practical nomogram from the SEER database to predict the prognosis of hepatocellular carcinoma in patients with lymph node metastasis. Ann Palliat Med. 2021;10:3847\u201363.","journal-title":"Ann Palliat Med"},{"key":"2424_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10552-020-01386-x","volume":"32","author":"X Zhang","year":"2021","unstructured":"Zhang X, El-Serag HB, Thrift AP. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. Cancer Causes Control. 2021;32:317\u201325.","journal-title":"Cancer Causes Control"},{"key":"2424_CR6","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1097\/SLA.0b013e31827da749","volume":"258","author":"H Nathan","year":"2013","unstructured":"Nathan H, Hyder O, Mayo SC, Hirose K, Wolfgang CL, Choti MA, Pawlik TM. Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis. Ann Surg. 2013;258:1022\u20137.","journal-title":"Ann Surg"},{"key":"2424_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2019.188314","volume":"1873","author":"D Anwanwan","year":"2020","unstructured":"Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873: 188314.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2424_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.21037\/hbsn-20-480","volume":"9","author":"DY Xie","year":"2020","unstructured":"Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9:452\u201363.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2424_CR9","doi-asserted-by":"publisher","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","volume":"29","author":"A Vogel","year":"2018","unstructured":"Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238\u201355.","journal-title":"Ann Oncol"},{"key":"2424_CR10","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"2424_CR11","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet (London, England). 2003;362:1907\u201317.","journal-title":"Lancet (London, England)"},{"key":"2424_CR12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/annonc\/mdn030","volume":"19","author":"S Collette","year":"2008","unstructured":"Collette S, Bonnetain F, Paoletti X, Doffoel M, Bouch\u00e9 O, Raoul JL, Rougier P, Masskouri F, Bedenne L, Barbare JC. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol Off J Eur Soc Med Oncol. 2008;19:1117\u201326.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2424_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.608548","volume":"10","author":"Z Song","year":"2020","unstructured":"Song Z, Wang Y, Zhang D, Zhou Y. A novel tool to predict early death in uterine sarcoma patients: a surveillance, epidemiology, and end results-based study. Front Oncol. 2020;10: 608548.","journal-title":"Front Oncol"},{"key":"2424_CR14","volume":"26","author":"Y Feng","year":"2020","unstructured":"Feng Y, Guo K, Jin H, Xiang Y, Zhang Y, Ruan S. A predictive nomogram for early mortality in stage IV gastric cancer. Med Sci Monit. 2020;26: e923931.","journal-title":"Med Sci Monit"},{"key":"2424_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017;67:93\u20139.","journal-title":"CA Cancer J Clin"},{"key":"2424_CR16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","volume":"22","author":"K Ishak","year":"1995","unstructured":"Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696\u20139.","journal-title":"J Hepatol"},{"key":"2424_CR17","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/ije\/dyz274","volume":"49","author":"A Janssens","year":"2020","unstructured":"Janssens A, Martens FK. Reflection on modern methods: Revisiting the area under the ROC Curve. Int J Epidemiol. 2020;49:1397\u2013403.","journal-title":"Int J Epidemiol"},{"key":"2424_CR18","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1097\/01.CCM.0000275267.64078.B0","volume":"35","author":"AA Kramer","year":"2007","unstructured":"Kramer AA, Zimmerman JE. Assessing the calibration of mortality benchmarks in critical care: the Hosmer-Lemeshow test revisited. Crit Care Med. 2007;35:2052\u20136.","journal-title":"Crit Care Med"},{"key":"2424_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak. 2006;26:565\u201374.","journal-title":"Med Decis Mak"},{"key":"2424_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1472-6947-8-53","volume":"8","author":"AJ Vickers","year":"2008","unstructured":"Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8:53.","journal-title":"BMC Med Inform Decis Mak"},{"key":"2424_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.729175","volume":"11","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Pu J, Zhang H. Development and validation of a simple-to-use nomogram to predict early death in metastatic pancreatic adenocarcinoma. Front Oncol. 2021;11: 729175.","journal-title":"Front Oncol"},{"key":"2424_CR22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/cam4.3613","volume":"10","author":"B Yan","year":"2021","unstructured":"Yan B, Su BB, Bai DS, Qian JJ, Zhang C, Jin SJ, Jiang GQ. A practical nomogram and risk stratification system predicting the cancer-specific survival for patients with early hepatocellular carcinoma. Cancer Med. 2021;10:496\u2013506.","journal-title":"Cancer Med"},{"key":"2424_CR23","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1186\/s12885-021-08490-4","volume":"21","author":"H Shen","year":"2021","unstructured":"Shen H, Deng G, Chen Q, Qian J. The incidence, risk factors and predictive nomograms for early death of lung cancer with synchronous brain metastasis: a retrospective study in the SEER database. BMC Cancer. 2021;21:825.","journal-title":"BMC Cancer"},{"key":"2424_CR24","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1186\/s12885-020-07635-1","volume":"20","author":"Z Huang","year":"2020","unstructured":"Huang Z, Hu C, Liu K, Yuan L, Li Y, Zhao C, Hu C. Risk factors, prognostic factors, and nomograms for bone metastasis in patients with newly diagnosed infiltrating duct carcinoma of the breast: a population-based study. BMC Cancer. 2020;20:1145.","journal-title":"BMC Cancer"},{"key":"2424_CR25","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.8497","volume":"8","author":"S Wan","year":"2020","unstructured":"Wan S, Nie Y, Zhu X. Development of a prognostic scoring model for predicting the survival of elderly patients with hepatocellular carcinoma. PeerJ. 2020;8: e8497.","journal-title":"PeerJ"},{"key":"2424_CR26","doi-asserted-by":"publisher","first-page":"21376","DOI":"10.1038\/s41598-020-78545-2","volume":"10","author":"K Liu","year":"2020","unstructured":"Liu K, Huang G, Chang P, Zhang W, Li T, Dai Z, Lv Y. Construction and validation of a nomogram for predicting cancer-specific survival in hepatocellular carcinoma patients. Sci Rep. 2020;10:21376.","journal-title":"Sci Rep"},{"key":"2424_CR27","volume":"352","author":"AJ Vickers","year":"2016","unstructured":"Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. BMJ (Clin Res ed). 2016;352: i6.","journal-title":"BMJ (Clin Res ed)"},{"key":"2424_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.835957","volume":"12","author":"X Chen","year":"2022","unstructured":"Chen X, Lu Y, Shi X, Han G, Zhao J, Gao Y, Wang X. Development and validation of a novel model to predict regional lymph node metastasis in patients with hepatocellular carcinoma. Front Oncol. 2022;12: 835957.","journal-title":"Front Oncol"},{"key":"2424_CR29","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.7496","volume":"7","author":"G Ye","year":"2019","unstructured":"Ye G, Wang L, Hu Z, Liang J, Bian Y, Zhan C, Lin Z. Risk and prognostic nomograms for hepatocellular carcinoma with newly-diagnosed pulmonary metastasis using SEER data. PeerJ. 2019;7: e7496.","journal-title":"PeerJ"},{"key":"2424_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.5604\/01.3001.0010.0290","volume":"16","author":"P Golabi","year":"2017","unstructured":"Golabi P, Jeffers T, Younoszai Z, Otgonsuren M, Sayiner M, Mishra A, Venkatesan C, Younossi ZM. Independent predictors of mortality and resource utilization in viral hepatitis related hepatocellular carcinoma. Ann Hepatol. 2017;16:555\u201364.","journal-title":"Ann Hepatol"},{"key":"2424_CR31","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.21037\/apm-20-1876","volume":"10","author":"K Zhang","year":"2021","unstructured":"Zhang K, Tao C, Wu F, Wu J, Rong W. A practical nomogram from the SEER database to predict the prognosis of hepatocellular carcinoma in patients with lymph node metastasis. Ann Palliative Med. 2021;10:3847\u201363.","journal-title":"Ann Palliative Med"},{"key":"2424_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209293","volume":"14","author":"Q-F Chen","year":"2019","unstructured":"Chen Q-F, Huang T, Shen L, Li W. Predictive value of a nomogram for hepatocellular carcinoma with brain metastasis at initial diagnosis: a population-based study. PLoS ONE. 2019;14: e0209293.","journal-title":"PLoS ONE"},{"key":"2424_CR33","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.7150\/jca.30365","volume":"10","author":"L Zhang","year":"2019","unstructured":"Zhang L, Yan L, Niu H, Ma J, Yuan B-Y, Chen Y-H, Zhuang Y, Hu Y, Zeng Z-C, Xiang Z-L. A nomogram to predict prognosis of patients with unresected hepatocellular carcinoma undergoing radiotherapy: a population-based study. J Cancer. 2019;10:4564\u201373.","journal-title":"J Cancer"},{"key":"2424_CR34","doi-asserted-by":"publisher","first-page":"16343","DOI":"10.1038\/s41598-021-95835-5","volume":"11","author":"B-Y Liang","year":"2021","unstructured":"Liang B-Y, Gu J, Xiong M, Zhang E-L, Zhang Z-Y, Chen X-P, Huang Z-Y. Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy. Sci Rep. 2021;11:16343.","journal-title":"Sci Rep"},{"key":"2424_CR35","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/bjc.2013.352","volume":"109","author":"Q Wang","year":"2013","unstructured":"Wang Q, Fiel MI, Blank S, Luan W, Kadri H, Kim KW, Manizate F, Rosenblatt AG, Labow DM, Schwartz ME, Hiotis SP. Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma. Br J Cancer. 2013;109:573\u201381.","journal-title":"Br J Cancer"},{"key":"2424_CR36","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1186\/s12885-018-4996-z","volume":"18","author":"H Liu","year":"2018","unstructured":"Liu H, Cen D, Yu Y, Wang Y, Liang X, Lin H, Cai X. Does fibrosis have an impact on survival of patients with hepatocellular carcinoma: Evidence from the SEER database? BMC Cancer. 2018;18:1125.","journal-title":"BMC Cancer"},{"key":"2424_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijsu.2020.06.018","volume":"80","author":"B Yan","year":"2020","unstructured":"Yan B, Bai DS, Zhang C, Qian JJ, Jin SJ, Jiang GQ. Characteristics and risk differences of different tumor sizes on distant metastases of hepatocellular carcinoma: a retrospective cohort study in the SEER database. Int J Surg. 2020;80:94\u2013100.","journal-title":"Int J Surg"},{"key":"2424_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.canlet.2016.05.022","volume":"379","author":"J Liu","year":"2016","unstructured":"Liu J, Chen S, Wang W, Ning BF, Chen F, Shen W, Ding J, Chen W, Xie WF, Zhang X. Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-\u03b2 pathways. Cancer Lett. 2016;379:49\u201359.","journal-title":"Cancer Lett"},{"key":"2424_CR39","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2147\/JHC.S272762","volume":"7","author":"J Zong","year":"2020","unstructured":"Zong J, Fan Z, Zhang Y. Serum tumor markers for early diagnosis of primary hepatocellular carcinoma. J Hepatocell Carcinoma. 2020;7:413\u201322.","journal-title":"J Hepatocell Carcinoma"},{"key":"2424_CR40","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.dld.2018.08.019","volume":"50","author":"F De Stefano","year":"2018","unstructured":"De Stefano F, Chacon E, Turcios L, Marti F, Gedaly R. Novel biomarkers in hepatocellular carcinoma. Dig Liver Dis. 2018;50:1115\u201323.","journal-title":"Dig Liver Dis"},{"key":"2424_CR41","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1155\/2012\/964036","volume":"32","author":"G Zhang","year":"2012","unstructured":"Zhang G, Ha SA, Kim HK, Yoo J, Kim S, Lee YS, Hur SY, Kim YW, Kim TE, Park YG, et al. Combined analysis of AFP and HCCR-1 as an useful serological marker for small hepatocellular carcinoma: a prospective cohort study. Dis Mark. 2012;32:265\u201371.","journal-title":"Dis Mark"},{"key":"2424_CR42","doi-asserted-by":"publisher","first-page":"10573","DOI":"10.3748\/wjg.v21.i37.10573","volume":"21","author":"N Tsuchiya","year":"2015","unstructured":"Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10573\u201383.","journal-title":"World J Gastroenterol"},{"key":"2424_CR43","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.4254\/wjh.v7.i8.1041","volume":"7","author":"S Colagrande","year":"2015","unstructured":"Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: diagnosis, indications, clinical and radiological follow-up. World J Hepatol. 2015;7:1041\u201353.","journal-title":"World J Hepatol"},{"key":"2424_CR44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5:87.","journal-title":"Signal Transduct Target Ther"},{"key":"2424_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12957-020-01887-8","volume":"18","author":"L Chen","year":"2020","unstructured":"Chen L, Sun T, Chen S, Ren Y, Yang F, Zheng C. The efficacy of surgery in advanced hepatocellular carcinoma: a cohort study. World J Surg Oncol. 2020;18:119.","journal-title":"World J Surg Oncol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02424-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02424-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02424-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T17:02:53Z","timestamp":1658250173000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02424-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2424"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02424-5","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"assertion":[{"value":"3 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols were approved by the National Cancer Institute (USA) to obtain research data on cancer patients (reference number 17461-Nov2020). This study was in line with the 1964 Helsinki Declaration and subsequent amendments or similar ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"348"}}